Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Orpea Nom.

Start price
Target price
Perf. (%)
€36.36
19.02.22
€32.00
19.02.23
-5.42%
05.03.22

Risky Investment
Canopy Growth Corp

Start price
Target price
Perf. (%)
€7.83
09.02.22
-
09.02.23
-12.11%
18.02.22

Probably not worthwhile Investment
Orpea Nom.

Start price
Target price
Perf. (%)
€34.38
06.02.22
€31.00
06.02.23
5.76%
19.02.22

Risky Investment
buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€6.22
06.02.22
-
06.02.23
-15.28%
20.02.22

Risky Investment
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€64.00
30.01.22
€65.00
30.01.23
-27.22%
14.03.22

Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
buy
Quoin Pharmaceuticals Ltd. ADR

Start price
Target price
Perf. (%)
€13.88
25.01.22
€25.00
25.01.23
9.01%
05.02.22

Could be worthwhile Investment >10% per year
Good culture
Capable Management
Few uniques
Teladoc Health Inc

Start price
Target price
Perf. (%)
€60.46
24.01.22
€52.00
24.01.23
5.86%
30.01.22

Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€6.43
23.01.22
-
23.01.23
7.21%
06.02.22

Could be very worthwhile Investment >20% year
buy
Jazz Pharmaceuticals plc

Start price
Target price
Perf. (%)
€130.15
12.01.22
-
12.01.23
12.55%
13.01.23

buy
Jazz Pharmaceuticals plc

Start price
Target price
Perf. (%)
€130.15
12.01.22
-
12.01.23
0.00%
12.01.22

buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€75.84
11.01.22
€82.00
11.01.23
-20.28%
24.01.22

Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
Novocure Ltd

Start price
Target price
Perf. (%)
€59.26
09.01.22
€51.00
09.01.23
8.34%
16.03.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€30.80
08.01.22
-
08.01.26
-46.20%
05.09.22

Probably not worthwhile Investment
buy
Gerresheimer AG

Start price
Target price
Perf. (%)
€80.40
07.01.22
-
07.01.23
-24.19%
13.03.22

buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€136.00
28.12.21
€142.00
28.12.22
-70.42%
29.12.22

Could be worthwhile Investment >10% per year
Capable Management
Future proof or reliable business model
buy
Opko Health Inc.

Start price
Target price
Perf. (%)
€4.65
28.12.21
-
28.12.22
-75.54%
29.12.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
buy
Uniqure B.V.

Start price
Target price
Perf. (%)
€19.00
27.12.21
-
27.12.22
8.55%
28.12.22

Could be worthwhile Investment >10% per year
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€143.65
27.12.21
-
27.12.22
-9.78%
09.01.22

Risky Investment
buy
Sage Therapeutics Inc.

Start price
Target price
Perf. (%)
€37.99
27.12.21
€42.00
27.12.22
-5.05%
28.12.22

Could be worthwhile Investment >10% per year
buy
Sartorius AG ST

Start price
Target price
Perf. (%)
€484.00
23.12.21
-
23.12.22
-15.70%
25.08.22

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€33.28
23.12.21
-
23.12.22
-41.87%
25.08.22

Teladoc Health Inc

Start price
Target price
Perf. (%)
€86.38
20.12.21
€66.00
20.12.22
-12.20%
11.01.22

Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
buy
Evotec SE ADR

Start price
Target price
Perf. (%)
€21.40
16.12.21
-
16.12.25
-60.75%
12.01.24

Could be worthwhile Investment >10% per year
buy
Evotec SE

Start price
Target price
Perf. (%)
€43.58
16.12.21
-
16.12.25
-60.99%
12.01.24

Could be worthwhile Investment >10% per year
buy
Neogen Corp.

Start price
Target price
Perf. (%)
€35.40
14.12.21
€38.00
14.12.22
-59.89%
15.12.22

Could be worthwhile Investment >10% per year